Eli Lilly and Company has announced its acquisition of Centessa Pharmaceuticals, a clinical-stage company specializing in orexin receptor 2 (OX2R) agonists aimed at treating excessive daytime sleepiness and related neurological disorders. This strategic move enhances Lilly’s neuroscience portfolio, providing access to Centessa’s lead candidate, cleminorexton (formerly ORX750), which has shown a promising profile in Phase 2a trials for narcolepsy types 1 and 2, as well as idiopathic hypersomnia.

The acquisition is particularly significant due to the OX2R pathway’s role in regulating the sleep-wake cycle, presenting a novel therapeutic target in neuroscience. Carole Ho, Lilly’s executive vice president, emphasized the potential of this mechanism to transform treatment paradigms for sleep-wake disorders. Centessa’s pipeline includes additional assets that could extend the therapeutic applications of OX2R agonists across various neurological, neurodegenerative, and neuropsychiatric conditions, thereby addressing a critical unmet need in these areas.

This acquisition not only accelerates the development timeline for OX2R-based therapies but also signals a shift in the landscape of sleep medicine research. The collaboration between Lilly and Centessa could expedite the translation of these findings into clinical practice, potentially leading to faster regulatory approvals and broader access to innovative treatments for patients suffering from sleep disorders. The deal, valued at approximately $6.3 billion upfront, with additional milestone payments, underscores the growing recognition of sleep health as a vital component of overall well-being and longevity.

Source: investor.lilly.com